Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUDOSE: DPD Phenotype-guided Dose Individualization of Fluoropyrimidine in Gastrointestinal Cancers
NCT06475352Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Jan 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastrointestinal cancer and colorectal cancer (CRC) (6 arms), sponsored by Unicancer. Primary endpoint: Proportion of fluoropyrimidine-induced grade >= 3 haematological and gastrointestinal toxicity at 42 days. Started Jan 2025; status: recruiting.
02
Conditions
gastrointestinal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06475352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475352.